Powered for a 2.5% mortality difference, found point estimate 0.7%
Is aligned with MEGA-ROX (powered for a 1.5% - in progress)
Meanwhile there is much to unpick in discussion here at #CCR25 for these results …
Including overly pragmatic collection of safety outcome ?
3/3

Results don’t find evidence for a difference.. paper live
2/3

shorturl.at/uVe6L

Though combining the design with the primary outcome distribution would bring the heebie-jeebies to most statisticians- they managed it.

Lovely example of ICEMAN for subgroups and reported in full in supp 3
2/2

This week saw the publication of the accompanying editorial from Rachel Phillips and Victoria Cornelius providing a really useful overview of learning from the series 3/7
@vcornelius.bsky.social
@rachpips.bsky.social
trialsjournal.biomedcentral.com/articles/10....

Many thanks to you Darren, fabulous couple of days and can feel some momentum building..exciting time ahead :)

So pleased you coming Ali, should be a great day. and look forward to meeting you in person.

With guest speakers: Tony Gordon, Fiona Lugg-Widger, Janis Best-Lane, Lindsey Masters, Cheryl Pugh, Andy King, David Murray, Marion Mafham

Hope to see many colleagues there
4/4

Day 2 will suit trial managers, data managers & trialists wanting to explore operations & DM considerations for
- Platform trials
- Routine data enabled trials
With guest speakers ...3/4

Day 1 will suit statisticians & statistically minded trialists. We will be delving into practical design and analysis considerations for:
MAMS
Platform
& Target trial emulation

With guest speakers: Max Parmar, Stuart Pocock, James Wason, Philip Pallmann, Shaun Seaman, Li Su 2/4

Yes it does for PCT but no evidence for CRP to reduce antibiotic duration.
Fantastic editorial by @marionkcampbell.bsky.social to critique methods used and provide perspective on interpretation of secondary analysis explored regarding the strength of the PCT intervention